The economic impact of introducing transurethral microwave thermotherapy in the treatment of benign prostatic hyperplasia: A scenario analysis

World Journal of Urology

Volumn 16, Issue 2, 1998, Pages 142-147

  Baltussen, R M P M ^a   Wielink, G ^a   Stoevelaar, H J ^a   Van Der Wilt, G J ^a   Severens, J L ^a   Ament, A J H A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST; DIATHERMY; ECONOMICS; HUMAN; MALE; METHODOLOGY; MICROWAVE RADIATION; PROSTATE HYPERTROPHY; STATISTICS; URETHRA;

COSTS AND COST ANALYSIS; DIATHERMY; HUMANS; MALE; MICROWAVES; PROSTATIC HYPERPLASIA; URETHRA;

EID: 0032387840     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003450050041     Document Type: Article

References (17)

1. Baltussen RMPM, Ament AJHA, Leidl RM (1996) Making cost assessments based on RCTs more useful to decisionmakers. Health Policy 37: 163-183
2. Boekhoven-Bosch (1997) Diagnostisch Kompas 1997 (in Dutch). Boekhoven-Bosch, Utrecht
3. Boekhoven-Bosch (1997) Farmacotherapeutisch Kompas 1997 (in Dutch). Boekhoven-Bosch, Utrecht
4. Bosch RJHL, Hop WJ, Kirkels WJ, Schröder FH (1995) Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology 46 [Suppl 3A]: 34-40
5. Centraal Bureau voor de Statistiek (CBS) (1997) Population month statistics. January 1997 (in Dutch). CBS. Voorburg/ Heerlen
6. Centraal Orgaan Tarieven Gezondheidszorg (1996) Tariffs for medical specialists excluding psychiatrists 1996 (in Dutch). Centraal Orgaan Tarieven Gezondheidszorg
7. Centraal Orgaan Tarieven Gezondheidszorg (1997) Vademecum 1997 (in Dutch). Centraal Orgaan Tarieven Gezondheidszorg
8. De la Rosette JJMCH, Tubaro A, Hofner K, Carter SSC (1994) Transurethral microwave thermotherapy: past, present and future. World J Urol 12: 352-356
9. d'Ancona FCH, Francisca EAE, Debruyne FMJH, De la Rosette JJMCH (1997) High-energy transurethral microwave thermotherapy in men with lower urinary tract symptoms. J Endourol 11: 285-289
10. Finkler SA (1982) The distinction between costs and charges. Ann Intern Med 96: 102-109
11. Garraway WM, Collins GN, Lee RJ (1991) High prevalence of benign prostatic hyperthrophy in the community. Lancet 338: 469-171
12. Jolleys JV. Donovan JL, Nanchanal K, Peters TJ, Abrams P (1994) Urinary symptoms in the community: how bothersome are they? Br J Urol 74: 551-555
13. National Medical Registration 1996 (1997) SIG Zorginformatie: data tape. SIG Cooperatie UA, Utrecht
14. Nederlandse Zorgfederatie (1997) The intramural health care in figures per January 1, 1996 (in Dutch). Nederlandse Zorgfederatie Drukkerij Nzf Faciliteiten, Utrecht
15. Roos NP, Wennberg JE, Malenka DJ (1989) Mortality and reoperation after operation and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med 320: 1120
16. Smith P (1995) Other non-medical therapies. In: Cockett ATK, Khoury F, Aso JY, Châtelain C, Denis L, Griffith K, Murphy G (eds) The 2nd international consultation on benign prostatic hyperplasia (BPH), Monaco. Scientific Communication Institute, Channel Islands, pp 575-600
17. Stoevelaar HJ, Van de Beek C, Casparie AF, Nijs HGT, McDonell J. Janknegt RA (1996) Variation in diagnostics and treatment of benign prostatic hyperplasia in urological practices (in Dutch). Ned Tijdschr Geneeskd 140: 837-842